The following is an excerpt from a statement from Genentech. Read the entire statement  HERE.
_________________________________________________________
Genentech has recently learned that a patient in the Phase III HAVEN 2 clinical trial developed a neutralizing anti-drug antibody.
For this patient, the anti-drug antibody resulted in reduced efficacy of HEMLIBRA.
